Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.39 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 4/20 | 0.35 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | NNMT | P40261 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.33 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | XPO1 | O14980 | 1/20 | 0.33 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.33 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8357219 | 0.82 | SCN5A (0.36) | AGBL2GPBAR1SMN1; SMN2SCN5ASCN9A | |
| SCHEMBL31349524 | 0.82 | KEAP1 (0.53) | AGBL2SMN1; SMN2SCN5ASCN9AKEAP1 | |
| SCHEMBL290570 | 0.82 | KEAP1 (0.53) | AGBL2SMN1; SMN2SCN5ASCN9AKEAP1 | |
| SCHEMBL27598069 | 0.82 | KEAP1 (0.53) | AGBL2SMN1; SMN2SCN5ASCN9AKEAP1 | |
| SCHEMBL4966985 | 0.82 | ALDH1A1 (0.36) | AGBL2GPBAR1SMN1; SMN2SCN5ASCN9A | |
| SCHEMBL168694 | 0.81 | CASP1 (0.42) | SCN5ASCN9ANNMT | |
| SCHEMBL9927092 | 0.80 | SCN5A (0.36) | AGBL2GPBAR1SMN1; SMN2SCN5ASCN9A | |
| SCHEMBL2582436 | 0.80 | OPRK1 (0.46) | SMN1; SMN2SCN5ASCN9AKDM4ENPC1 | |
| SCHEMBL8312609 | 0.80 | AGBL2 (0.39) | AGBL2GPBAR1SMN1; SMN2SCN5ASCN9A | |
| SCHEMBL16468484 | 0.80 | AGBL2 (0.41) | AGBL2SMN1; SMN2MAOBMAOAHCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117567461-A | Preparation method of vitamin Li Xigu intermediate | 佛山奕安赛医药科技有限公司 | 2024-02-20 | — | — | CN | claimed |
| WO-2025038462-A2 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2025-02-20 | — | — | WO | disclosed |
| WO-2025026266-A1 | COMPOUND AS LPAR1 ANTAGONIST, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 武汉朗来科技发展有限公司 | 2025-02-06 | — | — | WO | disclosed |
| CN-113527298-B | Macrocyclic lactam derivatives, preparation method and application thereof | 浙江海正药业股份有限公司 | 2025-01-03 | — | — | CN | disclosed |
| CN-117567461-A | Preparation method of vitamin Li Xigu intermediate | 佛山奕安赛医药科技有限公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-113527298-A | Macrocyclic lactam derivative, preparation method and application thereof | 浙江海正药业股份有限公司 | 2021-10-22 | — | — | CN | disclosed |
| US-20150087632-A1 | CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINES DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2015-03-26 | — | — | US | disclosed |
| US-8933085-B2 | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors | INCYTE CORPORATION (US) | 2015-01-13 | — | — | US | disclosed |
| US-20120149681-A1 | CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149681-A1 | CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | AGBL2 2527/4885GPBAR1 4313/4885SMN1; SMN2 4468/4885 |
| US-20150087632-A1 | CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINES DERIVATIVES AS JAK INHIBITORS | JAK2, JAK1, JAK3 | AGBL2 2608/4885GPBAR1 4173/4885SMN1; SMN2 4536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.